• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Illumina expects EU order to keep Grail a separate company

September 20, 2021 by David Barret Leave a Comment

September 20, 2021

By Foo Yun Chee

BRUSSELS (Reuters) -Illumina Inc expects an EU order to keep recently acquired Grail Inc as a separate company, the U.S. life sciences company said on Monday, hours after EU antitrust regulators warned of interim measures for closing the deal before their approval.

The company is likely to face other measures on top of the hold separate order, however, with the EU competition enforcer sending a warning to other companies.

Illumina finalised the Grail takeover last month and said it would hold the company separate while waiting for a European Commission decision on the deal, defying EU merger rules against gun-jumping.

Previous instances of gun-jumping have resulted in companies being hit with million-euro fines. Sanctions can be as much as 10% of a company’s global turnover.

“We had anticipated that the Commission would seek to impose a hold separate order, and this is the reason why it has already voluntarily agreed to such an arrangement; their proposals are based on Illumina’s voluntary undertakings,” Illumina said in a statement.

It said it would discuss certain changes suggested by the EU in the coming days.

The EU competition enforcer earlier on Monday said it had sent a statement of objections or charge sheet to the companies, setting out the interim measures it plans to take. It did not provide details.

Under EU merger rules, the competition watchdog can order companies to unwind their deals or sell off shares or assets acquired for violations.

Commission Vice-President Margrethe Vestager underlined the seriousness of Illumina’s actions, saying it was the first time companies had openly implemented a deal while regulators were still investigating.

“The standstill obligation is a cornerstone of our ex-ante merger control regime which aims at preventing harmful effects to competition while our review is ongoing,” she said in a statement.

The Commission said the interim measures aim to restore and maintain effective competition pending a final decision on the deal.

The Commission will make a final decision on the measures after receiving the companies’ response.

(Reporting by Foo Yun Chee in BrusselsEditing by Jan Harvey and Matthew Lewis)

Source Link Illumina expects EU order to keep Grail a separate company

David Barret
David Barret

Related posts:

  1. Lebanon agrees new government to tackle economic collapse
  2. India, Australia eye closer security ties as 9/11 anniversary marked
  3. Motor racing-Mercedes boss says F1 sprint format is ‘not fish, not meat’
  4. In Hungary, pope says anti-Semitism ‘fuse’ must not be allowed to burn

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Could This Be The Real Reason Humans Survived And Neanderthals Died Out?
  • Newly Discovered Snail Species Named After Studio Ghibli Co-Founder Is A Hairy Beauty
  • 2025 SC79 Is The Second-Fastest Asteroid Ever Found – And Only The Second Within Venus’ Orbit
  • When Red Devil Spiders Arrived On A New Island, Their Genome Dramatically Shrank In Half
  • Is This The World’s Oldest Story? Ancient Human Tale About The Seven Sisters May Be From 100,000 BCE
  • This Pill Is Actually A Tiny Printer That Repairs Internal Injuries Using Biocompatible Ink
  • “This Is Amazing”: Scientists Have Found Evidence Of A Long-Lost World Deep Within The Earth
  • From The Shiniest World To Lava And Eternal Darkness, These Are The Weirdest Known Planets
  • Do Sharks Have Bones?
  • The Zombie Awakens: A Volcano Is Showing “First Signs” Of Unrest After 700,000 Years Of Quiet
  • Two Of The World’s Biggest Earthquakes Seem To Be Synched Together
  • California Has A New State Snake, And It’s A 1.6-Meter-Long Giant
  • Experimental Nanoparticle “Super-Vaccines” Stop Breast, Pancreatic, And Skin Cancers In Their Tracks
  • New Nightmare Fuel Unlocked: Watch The First Known Capture Of A Shrew By A False Widow Spider
  • Peculiar Glow In The Milky Way Might Be Dark Matter Signature
  • “I Was Scared To Death”: Missouri’s Great Cobra Scare Of 1953 Was Eventually Solved After 35 Years
  • Two Spacecraft To Fly Through Comet 3I/ATLAS’s Ion Tail – Will They Be Able To Catch Something?
  • Pioneering Heavy Water Detection Suggests Earth’s Water Might Be Older Than The Sun
  • PhD Students’ Groundbreaking New Technique Rescues JWST’s Highest Resolution Data
  • Popcorn-Like Parasites And Weird Worms Among 14 New Species Discovered In The World’s Oceans
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version